Placebo Oral

DRUG11 trials

Conditions

Advanced CancerAtopic AsthmaBiliary Tract CancerCOVID-19Chronic Low-back PainDepression, AnxietyDiabetic Neuropathic PainDrug Resistant Epilepsy

Phase 1

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Oral WCK 2349

CompletedNCT04874324

WockhardtPharmacokinetics

Start: 2011-03-17End: 2011-06-25Updated: 2022-12-01

Phase 2

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma

CompletedNCT01448954

Pulmagen TherapeuticsAtopic Asthma

Start: 2011-09-30End: 2012-02-29Target: 36Updated: 2012-02-20

Assessment of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea

CompletedNCT02255045

Laboratorios Andromaco S.A.Dysmenorrhea

Start: 2014-06-27End: 2016-03-16Updated: 2019-05-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Active, not recruitingNCT02711553

Eli Lilly and CompanyAdvanced Cancer, Biliary Tract Cancer, Metastatic Cancer

Start: 2016-05-19End: 2026-12-31Updated: 2025-08-03

FMT for Remission of Active Ulcerative Colitis in Adults

WithdrawnNCT04202211

University of British ColumbiaInflammatory Bowel Diseases, Ulcerative Colitis

Start: 2022-03-31End: 2028-12-31Updated: 2023-05-10

Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T)

NCT04379479

National Polytechnic Institute, MexicoCOVID-19, SARS-CoV-2 Infection

Start: 2020-05-31End: 2020-12-31Target: 562Updated: 2020-05-07

Anti-protozoal Effect of Steroid Hormone 20-hydroxyecdysone

Active, not recruitingNCT04827537

Research Institute of Epidemiology, Microbiology and Infectious Diseases, UzbekistanGiardia Lamblia Infection

Start: 2021-01-01End: 2027-12-31Target: 200Updated: 2025-04-04

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

RecruitingNCT05986292

Eli Lilly and CompanyChronic Low-back Pain, Diabetic Neuropathic Pain, Osteoarthritis, Knee

Start: 2020-01-30End: 2027-04-01Target: 10000Updated: 2026-03-27

Phase 3

Vitamine D in Drug Resistant Epilepsy

CompletedNCT03475225

Centre Hospitalier St AnneDrug Resistant Epilepsy

Start: 2018-04-03End: 2020-12-09Updated: 2024-07-12

Phase 4

Azithromycin for Meibomian Gland Disease

TerminatedNCT03953118

University of California, San FranciscoDepression, Anxiety, Dry Eye, Neuropathic Eye Pain +1

Start: 2019-09-01End: 2021-07-01Updated: 2025-08-06

Unknown Phase

The Efficacy of Melatonin in the Burning Mouth Syndrome

NCT03788733

Universidad de MurciaSleep Disorders, Circadian Rhythm

Start: 2018-12-14End: 2019-12-14Target: 80Updated: 2018-12-28

PAIN Reports2024-10-162 citations

Vitamin D deficiency and effect of treatment on seizure frequency and quality of life parameters in patients with drug‐resistant epilepsy: A randomized clinical trial

Epilepsia2024-07-0913 citations

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.

2021-10-0157 citations

Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.

Journal of Clinical Oncology2020-02-0129 citations

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Oncotarget2018-02-1349 citations

Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial.

Journal of Clinical Oncology2017-02-018 citations